Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 2(3)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07332338Unknown

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

Role: lead

NCT07184385Phase 3Not Yet Recruiting

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

Role: lead

NCT05682560Phase 2Completed

Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

Role: lead

NCT03979742Phase 2Terminated

Umbilical Cord Blood Cell (MC001) Transplant Into Injured Spinal Cord Followed by the Locomotor Training

Role: lead

NCT06040476Phase 2Not Yet Recruiting

Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)

Role: lead

NCT01673932Phase 1Unknown

Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke

Role: collaborator

NCT01471613Phase 1Completed

Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury

Role: collaborator

All 7 trials loaded